CA-GSD/ANANDA
23.3.2021 16:02:07 CET | Business Wire | Press release
POSITIVE ALL THE WAY , an award-winning documentary about the Paralympics is now available internationally through Ananda Media. The short documentary, produced by The Foundation for Global Sports Development (GSD) and Sidewinder Films, won “Best Documentary” at the Together! 2020 Disability Film Festival .
With personal interviews and captivating footage, POSITIVE ALL THE WAY celebrates the power of adaptive sport to ignite the human spirit. The film chronicles the growth of the Paralympics under the leadership of Sir Philip Craven, who served as the President of the International Paralympic Committee from 2001 through 2017. Staying true to the integrity of sport and his personal principles, Sir Philip led the sports organization through moments of crisis – such as funding shortfalls and the 2016 Russian doping scandal - while positioning the Paralympics as a leading sports organization.
"Ever since I first met Steven Ungerleider and David Ulich in 2011, I very quickly realized that the true spirit of sport is embodied in everything that The Foundation for Global Sports Development and Sidewinder Films undertakes,” said Sir Philip Craven, who is featured in the film. “In my work with the International Paralympic Committee, I tried to follow that principle and to also follow very closely the vision of the IPC which was ’to enable Para athletes to achieve sporting excellence and inspire and excite the world.’ This is what I believe Sidewinder Films portrays in POSITIVE ALL THE WAY , and I am so pleased that they have partnered with Ananda Media in order that many more people can experience the true spirit of sport!”
"The Paralympic movement reaches across the globe and plays a remarkable role in promoting inclusion worldwide,” said David Ulich, director and producer of the film. “We are delighted to partner with Ananda Media to bring POSITIVE ALL THE WAY to international audiences who can join this movement.”
Dr. Steven Ungerleider, director and producer of POSITIVE ALL THE WAY, agreed. “Sport has the power to change the world, and we are passionate about telling those stories through film. Working with Ananda Media is a perfect fit, and we are honored to have our documentary featured alongside other compelling sports films.”
Ananda Media is a French-based distributor of adventure sports, travel, and healthy lifestyle content. Much of their content, including POSITIVE ALL THE WAY , is available on-demand for worldwide audiences. Visit http://anandamedia.net to learn more.
About Ananda Media
Ananda Media is a producer and distributor of action sports and adventure travel programming for television and digital media. We pride ourselves on working with the top independent film-makers, and TV Channels in order to ensure that our content offering is both unparalleled and broadcast, streamed or downloaded to millions around the world.
More info: http://anandamedia.net
About The Foundation for Global Sports Development and Sidewinder Films
The Foundation for Global Sports Development, established in 1996, was born out of a desire to promote and protect the best parts of sport. Guided by its original mission, the foundation delivers and supports initiatives that promote accessible, fair, and abuse-free sport for youth. The foundation achieves this objective through grants, awards, educational projects, and filmmaking. In 2015, the foundation launched its media company, Sidewinder Films, to inspire and educate audiences through films that shed light on the remarkable, untold stories that celebrate the sport of life. Visit www.globalsportsdevelopment.org and www.sidewinderfilms.org to learn more.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210323005297/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom